Commercialization of Novel IVDs: Highlights For Success in Diagnostics
December 12, 2017

Almac Diagnostics - TruSight® Tumor 170 – Clinical Trial Assay: Enabling Biomarker Led Clinical Trials and CDx Development
November 14, 2017

Characterization of Drop-In Events using Single-Cell/DEPArray™ Analysis
October 26, 2017

Commercialization Challenges and Opportunities for Diagnostics in Immuno-Oncology
October 11, 2017

Advances in Non-Invasive Prenatal Screening with an NGS CE-IVD Workflow
September 27, 2017

Novel Microfluidic Platforms Enrich Rare Cancer Cells to Study Heterogeneity and Identify Genetic Variants
August 2, 2017

NGS panels - from patient selection to CDx
June 19, 2017

What are Major Differences in Biomarker Test Adoption in European Countries? An Analysis of PD–L1 Testing in Italy & Germany
February 23, 2017

Controlling Pre-Analytical Variables in Liquid Biopsy Assay Development
January 26, 2017

The View is Better at the Pinnacle – Do RNA-Seq Molecular Diagnostics Add Greater Patient Insights for Oncology?
January 25, 2017